MEDICINA
Departamento
Complejo Asistencial Universitario de Burgos
Burgos, EspañaPublicaciones en colaboración con investigadores/as de Complejo Asistencial Universitario de Burgos (42)
2024
-
Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study
Circulation. Cardiovascular imaging, Vol. 17, Núm. 1, pp. e016206
-
Diagnosis and treatment of myocarditis and inflammatory cardiomyopathy. Consensus document of the SEC-Working Group on Myocarditis
Revista Espanola de Cardiologia
2023
-
Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study
Circulation, Vol. 147, Núm. 19, pp. 1436-1443
-
Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers
Clinical Microbiology and Infection, Vol. 29, Núm. 1, pp. 85-93
-
Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction
Clinical Research in Cardiology
-
Recommendations for the Implementation of the Self-Administration of Alpha-1 Antitrypsin
International Journal of COPD, Vol. 18, pp. 1691-1700
2022
-
A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort
European Journal of Preventive Cardiology, Vol. 29, Núm. 5, pp. 795-801
-
Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study
Gastroenterologia y Hepatologia, Vol. 45, Núm. 5, pp. 342-349
2021
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
-
Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review
Therapeutic Advances in Musculoskeletal Disease, Vol. 13
-
miR-320c Regulates SERPINA1 Expression and Is Induced in Patients With Pulmonary Disease
Archivos de Bronconeumologia, Vol. 57, Núm. 7, pp. 457-463
2020
-
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
Antiviral Research, Vol. 174
-
Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology
-
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25
2019
-
Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort
Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 55-64
-
Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort
Liver International, Vol. 39, Núm. 1, pp. 90-97
2018
-
Clinical predictors of candidemia in medical non-neutropenic, non-ICU patients. The CaMed score
International Journal of Clinical Practice, Vol. 72, Núm. 12
-
Factors affecting the selection of an inhaler device for COPD and the ideal device for different patient profiles. Results of EPOCA Delphi consensus
Pulmonary Pharmacology and Therapeutics, Vol. 48, pp. 97-103
2017
-
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort
Journal of Viral Hepatitis, Vol. 24, Núm. 4, pp. 304-311